These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33198652)

  • 1. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
    Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
    BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
    Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
    Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
    Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
    Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab.
    Masuda Y; Kananazawa Y; Matsuno K; Kakinuma D; Sakurazawa N; Ando F; Hagiwara N; Nomura T; Kato S; Yoshiyuki T; Yoshida H
    Anticancer Res; 2022 Mar; 42(3):1599-1605. PubMed ID: 35220257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial.
    Sato Y; Yamashita H; Yagi K; Nomura S; Seto Y
    Anticancer Res; 2024 Jul; 44(7):3125-3131. PubMed ID: 38925825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Ramucirumab/nab-paclitaxel for Previously Treated Advanced Gastric Cancer in Community Hospitals.
    Hashida S; Tanaka N; Takahashi Y; Onoda Y; Colvin HS; Ohashi R; Okamoto K
    Acta Med Okayama; 2021 Apr; 75(2):133-138. PubMed ID: 33953419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.
    Klempner SJ; Maron SB; Chase L; Lomnicki S; Wainberg ZA; Catenacci DVT
    Oncologist; 2019 Apr; 24(4):475-482. PubMed ID: 30470690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
    Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
    Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
    Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study.
    Hagiwara Y; Nakasya A; Matsumoto T; Ikoma T; Yamamoto Y; Kurioka Y; Tsuduki T; Kajiwara T; Nishina T; Yamashita N; Moriwaki T; Hyodo I
    J Gastrointest Oncol; 2022 Dec; 13(6):2769-2778. PubMed ID: 36636083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Efficacy and Safety of Nab-Paclitaxel plus Ramucirumab Therapy in Patients with Unresectable Advanced or Recurrent Gastric Cancer].
    Murakami K; Takeno A; Masuzawa T; Imada A; Takase K; Toya K; Yukawa Y; Kawai K; Sakamoto T; Katsura Y; Ohmura Y; Kagawa Y; Hata T; Takeda Y; Murata K
    Gan To Kagaku Ryoho; 2020 Mar; 47(3):493-495. PubMed ID: 32381926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer.
    Hayase S; Yamada L; Ujiie D; Nirei A; Tada T; Hanayama H; Monma T; Saze Z; Ohki S; Kono K
    Fukushima J Med Sci; 2019; 65(1):6-12. PubMed ID: 30996218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
    Zhang X; Zhou L; Zhou C; Shen L
    Adv Ther; 2024 Jun; 41(6):2112-2132. PubMed ID: 38619719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
    Kimura M; Usami E; Teramachi H; Yoshimura T
    J Oncol Pharm Pract; 2018 Sep; 24(6):403-411. PubMed ID: 28436252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.
    Matsumoto H; Kawazoe A; Shimada K; Fukuoka S; Kuboki Y; Bando H; Kojima T; Ohtsu A; Yoshino T; Doi T; Shitara K
    BMC Cancer; 2018 Jan; 18(1):120. PubMed ID: 29385993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).
    Kawabata R; Izawa N; Suzuki T; Nagahisa Y; Nishikawa K; Takahashi M; Nakamura M; Ishiguro A; Katsuya H; Hihara J; Manaka D; Negoro Y; Tsuji A; Takahashi T; Kochi M; Azuma M; Kadowaki S; Michimae H; Sunakawa Y; Ichikawa W; Fujii M
    Target Oncol; 2023 May; 18(3):359-368. PubMed ID: 37060430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
    Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
    Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
    Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
    Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
    Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.